<DOC>
	<DOCNO>NCT00104104</DOCNO>
	<brief_summary>The purpose trial study safety treat patient multiple myeloma least one bone lesion zoledronic acid 4mg intravenously ( IV ) every 3 - 4 week 2 year . Patients receive zoledronic acid infusion 15 minute 30 minute .</brief_summary>
	<brief_title>A Multiple Myeloma Trial Patients With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients 18 year age old Confirmed diagnosis Multiple Myeloma Stable renal function define two serum creatinine determination &lt; 3 mg/dL Calculated creatinine clearance great equal 30 mL/min ECOG Performance Status 0 1 Life expectancy great equal 9 month If patient childbearing potential , negative pregnancy test require screening , postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Ability comply trial requirement give informed consent . IV Bisphosphonate therapy 3 year . Patients diagnosis amyloidosis . Known hypersensitivity zoledronic acid bisphosphonates Pregnant patient lactate patient . Women childbearing potential medically recognize form contraception Patients uncontrolled cardiovascular disease , hypertension , Type 2 diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Z-MAX , multiple myeloma , zoledronic acid , bone metastasis</keyword>
</DOC>